Key Multiple Sclerosis Therapeutic Market Players:
- Abbvie Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Amgen Inc.
- Acorda Therapeutics, Inc.
- Biogen Inc.
- Bayer AG
- Bristol-Myers Squibb Company.
- F. Hoffman-La Roche Ltd
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Sanofi
- Viatris Inc.
Companies in the multiple sclerosis therapeutics adopting several strategies to strengthen their position and enhance their product portfolios. Extensive investment in R&D activities, and launching innovative new treatments, particularly in biologics and oral therapies are two of the highly adopted strategies. Companies are also focusing on securing regulatory approvals for new drugs. Collaboration and acquisition activities are maintaining the competition in the global multiple sclerosis therapeutic market. For instance, in October 2020, Eli Lilly and Company announced the acquisition of Disarm Therapeutics for an upfront payment of $135.0 million. Some of the prominent players include:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of multiple sclerosis therapeutic is evaluated at USD 30.74 billion.
Multiple Sclerosis Therapeutic Market size was over USD 29.37 billion in 2025 and is projected to reach USD 48.76 billion by 2035, growing at around 5.2% CAGR during the forecast period i.e., between 2026-2035.
North America commands a 45.7% share in the Multiple Sclerosis Therapeutic Market, fueled by strong regulatory support for innovative therapies and personalized medicines, driving growth through 2026–2035.
Key players in the market include Bayer AG, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd., Johnson & Johnson.
